HC Wainwright Has Pessimistic View of Savara FY2029 Earnings

Savara Inc. (NASDAQ:SVRA) – Research analysts at HC Wainwright dropped their FY2029 EPS estimates for Savara in a research report issued on Wednesday, August 12th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings per share of $0.09 for the year, down from their prior forecast of $0.11. The consensus estimate for Savara’s current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for Savara’s FY2030 earnings at $0.37 EPS.

Savara (NASDAQ:SVRA) last announced its earnings results on Tuesday, August 11th. The company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02).

Several other equities analysts have also recently weighed in on the company. Wall Street Zen upgraded Savara from a “sell” rating to a “hold” rating in a report on Saturday, June 13th. Oppenheimer started coverage on Savara in a research note on Friday, April 24th. They issued an “outperform” rating and a $11.00 price target for the company. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Savara in a research report on Friday, July 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Savara presently has a consensus rating of “Moderate Buy” and an average price target of $10.14.

Savara Trading Up 2.3%

Shares of NASDAQ:SVRA opened at $5.70 on Thursday. The company’s 50-day moving average price is $5.65 and its two-hundred day moving average price is $5.49. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.47 and a quick ratio of 13.47. Savara has a one year low of $2.43 and a one year high of $7.01. The stock has a market capitalization of $1.17 billion, a PE ratio of -9.83 and a beta of 0.29.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Rhumbline Advisers lifted its stake in Savara by 10.8% in the 2nd quarter. Rhumbline Advisers now owns 170,176 shares of the company’s stock valued at $388,000 after purchasing an additional 16,634 shares during the last quarter. Prudential Financial Inc. bought a new stake in Savara in the second quarter valued at approximately $30,000. XTX Topco Ltd acquired a new stake in shares of Savara in the second quarter valued at approximately $201,000. Invesco Ltd. lifted its position in shares of Savara by 35.4% in the second quarter. Invesco Ltd. now owns 120,891 shares of the company’s stock valued at $276,000 after buying an additional 31,633 shares during the last quarter. Finally, The Manufacturers Life Insurance Company boosted its stake in shares of Savara by 14.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 51,930 shares of the company’s stock worth $118,000 after acquiring an additional 6,449 shares during the period. 87.93% of the stock is currently owned by institutional investors and hedge funds.

Savara Company Profile

Savara Inc (NASDAQ:SVRA) is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare respiratory diseases. The company specializes in in-licensing, advancing and potentially bringing to market novel treatments that address severe pulmonary conditions with high unmet medical need.

The company’s lead candidate, Molgradex (recombinant human granulocyte-macrophage colony-stimulating factor, or GM-CSF), is under regulatory review for the treatment of autoimmune pulmonary alveolar proteinosis (PAP), a rare lung disease characterized by the accumulation of surfactant.